美国食品和药物管理局第三阶段豁免对单克隆抗体生物相似开发的净现值影响
Ranjit Ranbhor1, Priyanka Kulkarni2
1Business Development, Portfolio and Patents, Odin Pharmaceuticals LLC, Somerset, NJ, USA.
Biologics : targets & therapy
|February 19, 2026
概括
美国食品和药物管理局 (FDA)
科学领域:
- 生物制药开发 生物制药开发
- 监管科学 监管科学
- 卫生经济学 卫生经济学
背景情况:
- 美国食品和药物管理局 (FDA) 在2025年10月发布了指导意见,建议放弃对生物类似药的第三阶段比较疗效研究.
- 豁免取决于证明生物类似药与参考产品之间的分析相似性和药理动力学等价性.
研究的目的:
- 进行净现值 (NPV) 分析,将传统的生物类似药开发途径与第三阶段研究进行比较,以利用FDA提出的第三阶段豁免框架进行简化途径.
- 评估放弃关于生物类似药开发成本和时间表的第三阶段研究的经济影响.
主要方法:
- 开发了一个净当前价值 (NPV) 模型,将行业基准成本和时间表数据纳入第三阶段研究.
- 评估了高,中和低复杂度单克隆抗体生物相似方案的经济结果.
- 进行了敏感性分析,以评估参数变化的影响.
主要成果:
- 放弃第三阶段研究预计将使开发成本平均每项计划减少2500万美元 (18%的减少),并将开发时间缩短约1.5年 (21%的减少).
- 经风险调整后的净净值预计将提高2500万美元 (29%),最低可行的峰值销售门将从3亿美元降至2.5亿美元.
结论:
- 第三阶段豁免为符合FDA标准的具有良好特征的单克隆抗体生物仿制药提供了实质性的经济效益,包括降低成本和加快时间表.
- 实现这些好处取决于强大的分析数据,成功的豁免批准,适当的产品选择和FDA批准模式的实施后监测.
- 预计经济优势将从2026-2027年时间框架开始实现.
相关概念视频
01:28Drug Products: Biologics, Biosimilars and Interchangeables
288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288
01:13Bioequivalence studies: Biowaivers
292
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
292
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
24
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
24
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
489
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
489
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
322
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
322
01:26FDA Approved Drugs: Changes to Approved Drugs
286
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
286